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Abstract
Rationale Schizophrenia is a complex neuropsychiatric disor-
der characterized, in part, by impaired dopamine signaling.
TAK-063 is a selective inhibitor of phosphodiesterase 10A,
a key regulator of intracellular signaling pathways that is high-
ly expressed in the striatum.
Objective Safety, tolerability, and pharmacokinetics of TAK-
063 were evaluated in a phase 1 study.
Methods Healthy Japanese and non-Japanese volunteers were
randomized into dose cohorts of 3, 10, 30, 100, 300, and
1000 mg. Each fasting volunteer randomly received a single
dose of TAK-063 or placebo. Individuals from the 100-mg
cohort also received a post-washout, 100-mg dose under fed
conditions. A total of 84 volunteers enrolled (14 per cohort).
Results The most common drug-related adverse events (AEs)
were somnolence (33.3 %), orthostatic tachycardia (19.7 %),
and orthostatic hypotension (9.1 %). The three severe AEs
recorded occurred at the highest doses: orthostatic hypoten-
sion (n = 1; 300 mg) and somnolence (n = 2; 1000 mg). There
were no deaths, serious AEs, or discontinuations due to AEs.
TAK-063 exposure increased in a dose-dependent manner.
Median Tmax was reached 3 to 4 h postdose. Fed conditions
slowed absorption (Tmax = 6 h) and increased oral bioavailability.
Renal elimination was negligible. Safety and pharmacokinetic
parameters were similar between Japanese and non-Japanese
subjects. Impairments in cognitive function consistent with the
effects of other sedative or hypnotic agents were detected using a
validated, computerized cognition battery, CNS Vital Signs.
Conclusions TAK-063 was safe and well tolerated at doses up
to 1000 mg and demonstrated a pharmacokinetic profile
supporting once-daily dosing. Further evaluation of the clini-
cal safety and efficacy of TAK-063 is warranted.
Keywords Schizophrenia . Pharmacokinetics . Safety .
Phosphodiesterase 10A . Single-rising dose . Oral
Introduction
Schizophrenia is a neuropsychiatric disorder of complex eti-
ology. Associated with lifelong disability and a poor quality of
life, schizophrenia presents as a triad of positive, negative, and
cognitive symptoms (Citrome 2014; de Araujo et al. 2012).
Current standard of care (first- and second-generation anti-
psychotics) are thought to achieve their therapeutic effects
primarily through antagonism of the dopamine D2 receptor
subtype (Farde et al. 1992; Ginovart and Kapur 2012).
Numerous studies have demonstrated the efficacy of antipsy-
chotics in ameliorating positive symptoms (Lieberman et al.
2005), though a significant proportion of patients experience
residual symptoms that are not responsive to therapy (Lehman
et al. 2004; Tarrier 1987). Further, these drugs have little to
modest clinical effects on cognitive and negative symptoms
(Citrome 2014; Lehman et al. 2004; Leucht et al. 2009).
Current antipsychotics are often associated with a multi-
tude of adverse events (AEs), including extrapyramidal symp-
toms (EPS) and hyperprolactinemia, which are due, at least in
part, to excessive dopamine D2 receptor antagonism in the
striatum and the pituitary gland, respectively (Farde et al.
1992; Ginovart and Kapur 2012). Metabolic disturbances
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affecting weight, lipid profile, and blood glucose levels have
also been observed following treatment with current agents or
therapies (Ginovart and Kapur 2012; Leucht et al. 2009;
Newcomer 2007). These dose-limiting side effects, along with
the persistent cognitive, negative, and psychotic symptoms
also associated with typical and atypical antipsychotics, un-
derscore the need for new pharmacologic treatment options
(Citrome 2014).
TAK-063 is a potent and selective phosphodiesterase
10A (PDE10A) inhibitor in clinical development for the
treatment of schizophrenia (Suzuki et al. 2015). PDE10A
is an intracellular enzyme that degrades cyclic adenosine
monophosphate pathway (cAMP) and cyclic guanosine
monophosphate pathway (cGMP)—second messenger
molecules with important effects on neuronal excitability
(Fujishige et al. 1999; Song et al. 2006; Threlfell et al.
2009). Unlike other phosphodiesterases, PDE10A is selec-
tively expressed in the GABAergic medium-spiny neurons
(MSNs), the predominant neuronal population of the stria-
tum (Kreitzer 2009; Sano et al. 2008; Seeger et al. 2003;
Suzuki et al. 2015).
In MSNs of both the direct and indirect pathways,
PDE10A mediates signaling activity downstream of dopa-
mine D1 (direct) and D2 (indirect) receptor activation
(Sano et al. 2008; Siuciak et al. 2006; Suzuki et al.
2015). PDE10A-mediated modulation of signaling
through these two distinct dopamine receptor subtypes
affects the sensitivity of MSNs to glutamatergic inputs,
and thereby partly regulates the opposing effects of both
the direct and indirect pathways (Siuciak et al. 2006;
Surmeier et al. 2007). PDE10A may represent an impor-
tant regulatory locus within the striatal signaling network;
it receives inputs from cortical, thalamic, and subcortical
areas that regulate sensory processing, motor planning,
and goal-directed behavior (Alexander et al. 1986;
Macpherson et al. 2014; Perez-Costas et al. 2010).
Notably, the clinical expression of schizophrenia includes
significant deficits in these and related higher-order pro-
cesses, making it difficult for patients to perform basic
tasks (Citrome 2014; de Araujo et al. 2012).
Taken together, the preclinical data validate PDE10A as
a potential target for therapeutic intervention (Grauer et al.
2009; Kehler and Nielsen 2011), and support further inves-
tigation of the safety, tolerability, and potential multidi-
mensional efficacy of selective PDE10A inhibitors in peo-
ple with schizophrenia (Heckman et al. 2016). Here, the
results of a phase 1, randomized, placebo-controlled,
single-rising dose study exploring the pharmacokinetic
(PK), and pharmacodynamic (PD) profiles of TAK-063 in
healthy subjects are reported. As prior reports have noted
ethnic differences in pharmacokinetics of several com-
pounds, results for Japanese and non-Japanese subjects
are reported (Fukunaga et al. 2011).
Methods
Study design and subjects
The study was conducted at a single site in the USA in com-
pliance with Institutional Review Board regulations, Good
Clinical Practice regulations and guidelines, and all local
regulations.
Healthy Japanese and non-Japanese subjects between 18
and 55 years of age were recruited to participate in the study.
Criteria for exclusion included prior treatment with any inves-
tigational compound within 30 days of the first TAK-063
dose, a positive test for drugs of abuse or nicotine, and an
increased risk for suicide. Subjects were randomized into 1
of 6 dose cohorts (3, 10, 30, 100, 300, and 1000 mg), with
each cohort containing 11 TAK-063 subjects (five Japanese,
six non-Japanese) and three placebo subjects (one Japanese,
two non-Japanese) receiving a single dose under fasting con-
ditions. Following a washout period of 7 days, subjects in
cohort 3 (100 mg) received the same dose (100 mg) but under
fed conditions.
Study endpoints
The study assessed safety and tolerability in all subjects for the
4-day study duration. The primary endpoints were the percent-
age of subjects who experienced at least one treatment-
emergent adverse event (TEAE), as well as the percentage of
subjects who met predefined criteria for safety laboratory
tests, vital sign measurements, and safety parameters follow-
ing TAK-063 administration. The secondary endpoints were
PK parameters for TAK-063 and M-I, assessing drug expo-
sure at each dose, and the effect of food coadministration on
TAK-063 PK. Exploratory endpoints included the effects of
TAK-063 on domains of cognition as assessed by a comput-
erized battery, CNS Vital Signs (CNSVS).
Safety assessments
Adverse events, clinical laboratory tests, vital signs, 12-lead
electrocardiograms (ECGs), and Columbia-Suicide Severity
Rating Scale (C-SSRS) were all monitored. Intensity of AEs
was classified as mild, moderate, or severe, and each AE was
classified as to its relation to study drug.
Laboratory tests evaluated hematology, serum chemistry,
urine, and hormone levels. Vital signs and ECGs were collect-
ed at screening, check-in, within 1 h predose, serially
postdose, and at study exit, while the C-SSRS was adminis-
tered at screening, check-in, and study exit. Any events report-
ed on the C-SSRS and clinically significant laboratory abnor-
malities were reported as AEs.
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Pharmacokinetic and pharmacodynamic assessments
Serial plasma and urine samples were collected from all sub-
jects prior to dosing and at specific time points or intervals up
to 96 h postdose. Pharmacokinetic samples were processed
immediately and frozen at −20 °C as duplicate sets. Plasma
concentrations of TAK-063 and its metabolite M-I were sub-
sequently measured by validated liquid chromatography-
tandem mass spectrometry with a validated range of 0.5 to
1000 ng/mL for both analytes.
The PK parameters analyzed for TAK-063 and its metabo-
lite M-I in plasma and urine included area under the plasma
concentration-time curve from time 0 to infinity (AUC(0-inf)),
maximum observed plasma concentration (Cmax), time to
reach Cmax (Tmax), terminal elimination half-life (T1/2), oral
clearance (CL/F), volume of distribution (Vz/F), and renal
clearance (CLr). Metabolite-to-parent ratios were estimated
from Cmax and AUC(0-inf) data.
Cognitive flexibility, attention, executive function, memo-
ry, reasoning, motor control, psychomotor speed, reaction
time, and information processing speed were assessed predose
and at 2 and 6 h following TAK-063 treatment using the
CNSVS computerized cognition battery. The CNSVS cogni-
tion battery is a well-validated, sensitive measure and included
the following tests: verbal and visual memory (VBM and
VIM) tests, finger-tapping test, symbol digit coding test,
Stroop test, shifting attention test, the nonverbal reasoning
test, and the 4-part continuous performance test (Gualtieri
and Johnson 2006). Standardized domain scores for cognitive
flexibility, composite memory, executive functioning, pro-
cessing speed, psychomotor speed, reaction time, reasoning,
sustained attention, verbal memory, visual memory, and work-
ing memory were reported. In all domains, a decrease in the
standardized domain score is indicative of impairment.
Statistical analysis
All statistical analyses were generated using SAS Version 9.2
(SAS, Cary, NC, USA). The PK parameters were derived
using non-compartmental methods with WinNonlin
Enterprise Version 6.3 (Pharsight Corp., Mountain View,
CA, USA). Frequency or descriptive statistics were used for
summary of data. Where indicated, percent coefficient of var-
iation was included in the summary of continuous data. All
statistical tests were 2-tailed at α = 0.05 level for significance
unless otherwise stated. A power model was used to evaluate
dose proportionality by race for fasted subjects; in the event of
no observed race effect, dose proportionality was assessed for
all subjects. To evaluate the food effect, a paired t test was
performed on Tmax and natural log-transformed Cmax, and
AUCs. An ANCOVA model with baseline scores and race




A total of 84 subjects were enrolled in this study, with
comparable distribution of male and female subjects in
each dose group (Table 1). The mean age and body mass
index were similar among all groups and ranged from
30.5 to 36.1 years and 22.6 to 24.5 kg/m2, respectively.
Over 90 % of subjects were of non-Hispanic/non-Latino
ethnicity, and the racial distribution across subjects was
approximately half Asian, one-quarter Caucasian, and
one-quarter Black/African American.
Safety
No deaths or other serious AEs were reported, and no subject
discontinued treatment because of AEs. Across all cohorts, 32
of 66 subjects experienced a total of 57 drug-related AEs
(Table 2). The most common drug-related AEs following
TAK-063 treatment were somnolence (33.3 %), orthostatic
tachycardia (19.7 %), and orthostatic hypotension (10.6 %).
Reports of EPS or EPS-like events were infrequent across all
subjects—one Japanese subject reported muscle tightness in
the 30-mg treatment group. The majority of AEs (55/63;
87.3 %) were of mild intensity. Three adverse events were
reported as severe intensity: one subject had orthostatic hypo-
tension (300 mg), and two had somnolence (1000 mg). The
total incidence of TEAEs within Japanese subjects treated
with TAK-063 was 43.3 % compared to 52.8 % in non-
Japanese subjects (Online Resources 1 and 2). None of the
physical examination parameters, clinical laboratory tests, C-
SSRS findings, or ECGs was considered clinically significant
for any subject. There was an increased incidence of abnormal
readings for blood pressure and pulse rate, mostly occurring in
subjects in the 1000-mg TAK-063 treatment group.
Pharmacokinetic properties of TAK-063
The mean concentration-time profiles of TAK-063 and M-I in
all subjects were measured over a period of 96 h following
administration of single oral doses (Fig. 1). Under fasting
conditions, TAK-063 was absorbed with a median Tmax value
of 3 to 4 h postdose and eliminated with a mean T1/2 value of
15 to 25 h postdose across all subjects (Fig. 1).M-I exhibited a
similar mean plasma concentration-time profile to the parent
TAK-063. No substantial differences for either analyte were
observed between Japanese and non-Japanese subjects
(Online Resource 5).
The plasma and urine PK parameters of TAK-063 and M-I
under fasting conditions are presented in Table 3. Exposure to
TAK-063 was less than dose-proportional with AUC values
increasing up to 26-fold in response to the 333-fold increase in
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TAK-063 dose investigated in this study (Fig. 2). The
intersubject variability of TAK-063 Cmax and AUC(0-inf)
values was generally moderate across doses (18–81 % coeffi-
cient of variation). Clearance of TAK-063 (CL/F) increased
with dose whereas renal elimination was negligible (Table 3).
Similar PK properties were observed for TAK-063 M-I (M-I
to parentCmax and AUC ratios: 0.82–0.97 and 0.78–1.04). PK
parameters for Japanese and non-Japanese subjects are report-
ed in Online Resources 3 and 4. For both TAK-063 and M-I,
no substantial differences in pharmacokinetics were observed
between Japanese and non-Japanese subjects.
An evaluation of the effects of food on absorption and oral
bioavailability of TAK-063 following a 100-mg dose found
tha t TAK-063 was absorbed more s lowly when
coadministered with a standard meal, (median Tmax = 6 h,
compared with 3 to 4 h under fasting condition), and oral
bioavailability of TAK-063 was approximately 2-fold greater
than under fasting conditions (Table 4). Terminal elimination,
fraction of dose excreted, and renal clearance were not sub-
stantially altered under fed conditions. M-I showed similar PK
properties to TAK-063 in the fasting and fed arms, with M-I to
parent ratios of 0.97 and 1.00; 0.99 and 0.98; and 1.04 and
1.00 for Cmax, AUC(0-tlqc), and AUC(0-inf), respectively. No
observed differences were apparent between Japanese and
non-Japanese subjects in either fasting or fed condition (data
not shown).
Effects of TAK-063 on cognition
An overall dose effect of TAK-063 relative to placebo was
observed at 2 and 6 h postdose (Online Resource 6) on the
domains of cognitive flexibility, executive functioning,


























Somnolence 0 0 0 4 (36.4) 7 (63.6) 5 (45.5) 6 (54.5) 22 (33.3)
Orthostatic
tachycardia
1 (5.6) 2 (18.2) 0 1 (9.1) 2 (18.2) 1 (9.1) 7 (63.6) 13 (19.7)
Orthostatic
hypotension
3 (16.7) 0 0 0 1 (9.1) 1 (9.1) 5 (45.5) 7 (10.6)
Vomiting 0 0 0 0 1 (9.1) 1 (9.1) 1 (9.1) 3 (4.5)
Nausea 0 0 0 2 (18.2) 0 0 1 (9.1) 3 (4.5)
Dizziness 0 0 0 1 (9.1) 0 1 (9.1) 1 (9.1) 3 (4.5)
Dysarthria 0 0 0 0 0 0 1 (9.1) 1(1.5)
Headache 2 (11.1) 0 0 0 1 (9.1) 1 (9.1) 0 2 (3.0)
Anxiety 0 0 0 0 0 0 1 (9.1) 1 (1.5)
Hypotension 0 0 0 0 1 (9.1) 0 0 1 (1.5)
Blurred vision 0 0 0 0 0 0 1 (9.1) 1 (1.5)
Epistaxis 0 0 0 1 (9.1) 0 0 0 1 (1.5)
Muscle
tightness
0 0 0 1 (9.1) 0 0 0 1 (1.5)
Fig. 1 Mean plasma
concentration-time profiles of
TAK-063 and M-I (metabolite)
across all subjects by dosing
group
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processing speed, psychomotor speed, and visual memory. In
addition, statistically significant effects were noted at the 2-h
timepoint in composite memory, reaction time, and verbal
memory; the effects in these domains were not significant at
the 6-h timepoint. A decrease from baseline in domain score in
these cognitive domains, indicative of impairment, was gen-
erally observed following TAK-063 administration relative to
the changes observed after placebo administration (Online
Resource 6). No statistically significant differences were ob-
served between Japanese and non-Japanese subjects for any of
the neurocognitive domains tested (data not shown).
Discussion
In this single-ascending-dose study, the PK, PD, safety, and
tolerability profiles of TAK-063 in healthy subjects were eval-
uated under fasting and fed conditions. The results show that
TAK-063 is safe and well tolerated following administration
of a single dose in Japanese and non-Japanese volunteers.
Specifically, treatment with a single dose of TAK-063 was
not associated with hyperprolactinemia, hyperglycemia, or
other metabolic disturbances that are often observed with cur-
rent antipsychotics (Henderson et al. 2005; Lieberman et al.
2005; Miyamoto et al. 2005). Somnolence was the most com-
mon TEAE associated with TAK-063 treatment. Across all
doses, the incidence of EPS-like AEs was negligible, occur-
ring in only one Japanese patient at 30 mg (mild muscle tight-
ness); it resolved without intervention. This may suggest that
single doses of TAK-063may have a relatively low propensity
for EPS. No adverse events were considered dose-limiting,
and a maximum tolerated dose was not defined.
TAK-063 and M-I exposure increased in a dose-
dependent manner. The nonlinear PK of TAK-063 may
be due to limitations in drug absorption and oral bioavail-
ability; the low aqueous solubility of TAK-063 is consis-
tent with preclinical toxicology studies in which the drug
was excreted in the feces, suggesting that the test article
was not absorbed. Drug absorption and oral bioavailability
can be increased through coadministration with food, and
TAK-063 treatment under fed conditions exhibited slower
absorption and increased oral bioavailability. These results
are consistent with previous studies in animal models
assessing TAK-063’s solubility in the fed state.
The analyses of cognition data suggest that single
doses of TAK-063 ≥ 100 mg cause impairments in cogni-
tive flexibility, executive functioning, processing and psy-
chomotor speed, and visual memory. While the small
sample size limits the interpretation of the cognition re-
sults, higher incidences and severity of somnolence were
also reported at higher doses of TAK-063 and these ef-
fects may be similar to the effects on cognition of other
sedative or hypnotic agents (Miyata et al. 2015; Stranks
and Crowe 2014). Together, these data will inform subse-
quent analyses of TAK-063 studies in subjects with
schizophrenia.
Selective PDE10A inhibitors represent a potentially
new strategy in the treatment of schizophrenia, with pre-
liminary evidence supporting a favorable safety and toler-
ability profile, and preclinical studies suggest PDE-10A
inhibitors may have the potential for efficacy across mul-
tiple symptom domains (Grauer et al. 2009; Kehler and
Nielsen 2011; Suzuki et al. 2015). The data reported in
this study demonstrate the safety and tolerability of TAK-
063 following a single dose of up to 1000 mg and support
once-daily dosing. Taken together, these preliminary find-
ings are encouraging and support the need for additional
studies of TAK-063 in patients with schizophrenia. A
clinical trial to characterize the PK and PD profiles of
multiple rising doses of TAK-063 in patients with schizo-
phrenia has recently been completed (NCT01879722). A
phase 2 study of the efficacy and safety of TAK-063 for
the treatment of acute exacerbations of the symptoms of
s c h i z o p h r e n i a i s c u r r e n t l y b e i n g c o n d u c t e d
(NCT02477020).
Fig. 2 Box plotsa of TAK-063 exposure under fasting conditions across
all subjects by dosing group. a Middle lines of boxes represent median
values; top and bottom borders show lower and upper quartiles; whiskers
represent minima and maxima
Table 4 PK parameters for food-effect arm following oral administra-
tion of 100 mg TAK-063 in Japanese and non-Japanese subjects
TAK-063 M-I
Estimate 90 % CI Estimate 90 % CI
Cmax (ng/mL) 1.86 1.54, 2.25 1.95 1.63, 2.33
AUC(0-inf) (ng·h/mL) 1.78 1.52, 2.09 1.75 1.44, 2.12
CI confidence interval; M-I metabolite
Psychopharmacology (2016) 233:3787–3795 3793
Acknowledgments Some data contained in this manuscript were
presented in abstract form (Tsai M, Macek T, Chrones L, Xie J,
Gevorkyan H. Safety, Tolerability and Pharmacokinetics of TAK-
063, a PDE10A Inhibitor, After a Single Dose in Healthy Japanese
and Non-Japanese Subjects. American Society for Clinical
Psychopharmacology 2015).
Contributors Max Tsai, Thomas Macek, and Lambros Chrones de-
signed the study or were primarily responsible for the sponsor oversight
and conduct of the study. Max Tsai did the PK analyses while Jinhui Xie
did the statistical analysis. Hakop Gevorkyan was the principal investi-
gator. All authors contributed to and have approved the final manuscript.
Editorial support was provided by inVentiv Medical Communications,
New York, NY. inVentiv prepared the preliminary draft of the manuscript
under the direction of the lead author, Max Tsai, PhD. Dr. Tsai and the
other authors maintained full editorial control of the manuscript and its
conclusions throughout its development.
Compliance with ethical standards
Role of funding source Funding for this study was provided by Takeda
Pharmaceutical Company, Limited.
Conflicts of interest Max Tsai, ThomasMacek, Lambros Chrones, and
Jinhui Xie are employees of Takeda Development Center Americas, Inc.,
Deerfield, IL. Hakop Gevorkyan is an employee of California Clinical
Trials Medical Group, Glendale, CA, and was Principal Investigator of
the study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Alexander GE, DeLong MR, Strick PL (1986) Parallel organization of
functionally segregated circuits linking basal ganglia and cortex.
Annu Rev Neurosci 9:357–381
Citrome L (2014) Unmet needs in the treatment of schizophrenia: new
targets to help different symptom domains. J Clin Psychiatry
75(Suppl 1):21–26
de Araujo AN, de Sena EP, de Oliveira IR, Juruena MF (2012)
Antipsychotic agents: efficacy and safety in schizophrenia. Drug
Healthc Patient Saf 4:173–180
Farde L, NordstromAL,Wiesel FA, Pauli S, Halldin C, Sedvall G (1992)
Positron emission tomographic analysis of central D1 and D2 dopa-
mine receptor occupancy in patients treated with classical neurolep-
tics and clozapine. Relation to extrapyramidal side effects. ArchGen
Psychiatry 49(7):538–544
Fujishige K, Kotera J, Omori K (1999) Striatum- and testis-specific phos-
phodiesterase PDE10A isolation and characterization of a rat
PDE10A. Eur J Biochem 266(3):1118–1127
Fukunaga S, Kusama M, Arnold FL, Ono S (2011) Ethnic differences in
pharmacokinetics in new drug applications and approved doses in
Japan. J Clin Pharmacol 51:1237–1240
Ginovart N, Kapur S (2012) Role of dopamine D(2) receptors for anti-
psychotic activity. Handb Exp Pharmacol 212:27–52
Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, Langen
B, Logue S, Brennan J, Jiang L, Charych E, Egerland U, Liu F,
Marquis KL, Malamas M, Hage T, Comery TA, Brandon NJ
(2009) Phosphodiesterase 10A inhibitor activity in preclinical
models of the positive, cognitive, and negative symptoms of schizo-
phrenia. J Pharmacol Exp Ther 331(2):574–590
Gualtieri CT, Johnson LG (2006) Reliability and validity of a computer-
ized neurocognitive test battery, CNS vital signs. Arch Clin
Neuropsychol 21:623–643
Heckman PR, van Duinen MA, Bollen EP, Nishi A, Wennogle LP,
Blokland A, Prickaerts J (2016) Phosphodiesterase inhibition and
regulation of dopaminergic frontal and striatal functioning: clinical
implications. Int J Neuropsychopharmacol. doi:10.1093
/ijnp/pyw030
HendersonDC, Cagliero E, Copeland PM,Borba CP, Evins E, HaydenD,
Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D,
Goff DC (2005) Glucose metabolism in patients with schizophrenia
treated with atypical antipsychotic agents: a frequently sampled in-
travenous glucose tolerance test and minimal model analysis. Arch
Gen Psychiatry 62(1):19–28
Kehler J, Nielsen J (2011) PDE10A inhibitors: novel therapeutic drugs
for schizophrenia. Curr Pharm Des 17(2):137–150
Kreitzer AC (2009) Physiology and pharmacology of striatal neurons.
Annu Rev Neurosci 32:127–147
Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL,
Perkins DO, Kreyenbuhl J, American Psychiatric Association;
Steering Committee on Practice Guidelines (2004) Practice guide-
line for the treatment of patients with schizophrenia, second edition.
Am J Psychiatry 161(2 Suppl):1–56
Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009) Second-
generation versus first-generation antipsychotic drugs for schizo-
phrenia: a meta-analysis. Lancet 373(9657):31–41
Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA,
Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD,
Severe J, Hsiao JK, Clinical Antipsychotic Trials of Intervention
Effectiveness (CATIE) Investigators (2005) Effectiveness of anti-
psychotic drugs in patients with chronic schizophrenia. N Engl J
Med 353(12):1209–1223
Macpherson T, Morita M, Hikida T (2014) Striatal direct and in-
direct pathways control decision-making behavior. Front
Psychol 5:1301
Miyamoto S, Duncan GE, Marx CE, Lieberman JA (2005)
Treatments for schizophrenia: a critical review of pharmacol-
ogy and mechanisms of action of antipsychotic drugs. Mol
Psychiatry 10(1):79–104
Miyata A, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic
B, Ebe K, Noda A, Noda Y, Iritani S, Ozaki N (2015) The effects of
acute treatment with ramelteon, triazolam, and placebo on driving
performance, cognitive function, and equilibrium function in
healthy volunteers. Psychopharmacology (Berl) 232(12):2127–
2137
Newcomer JW (2007)Metabolic considerations in the use of antipsychot-
ic medications: a review of recent evidence. J Clin Psychiatry
68(Suppl 1):20–27
Perez-Costas E, Melendez-Ferro M, Roberts RC (2010) Basal ganglia
pathology in schizophrenia: dopamine connections and anomalies.
J Neurochem 113(2):287–302
Sano H, Nagai Y, Miyakawa T, Shigemoto R, Yokoi M (2008)
Increased social interaction in mice deficient of the striatal
medium spiny neuron-specific phosphodiesterase 10A2. J
Neurochem 105(2):546–556
Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear
J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD,
Wylie PG, Menniti FS (2003) Immunohistochemical localization of
PDE10A in the rat brain. Brain Res 985(2):113–126
3794 Psychopharmacology (2016) 233:3787–3795
Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC,
Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS,
Schmidt CJ (2006) Genetic deletion of the striatum-enriched phos-
phodiesterase PDE10A: evidence for altered striatal function.
Neuropharmacology 51(2):374–385
Song XJ, Wang ZB, Gan Q, Walters ET (2006) cAMP and cGMP
contribute to sensory neuron hyperexcitability and hyperalgesia
in rats with dorsal root ganglia compression. J Neurophysiol
95(1):479–492
Stranks EK, Crowe SF (2014) The acute cognitive effects of zopiclone,
zolpidem, zaleplon, and eszopiclone: a systematic review and meta-
analysis. J Clin Exp Neuropsychol 36:691–700
Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2
dopamine-receptor modulation of striatal glutamatergic signaling
in striatal medium spiny neurons. Trends Neurosci 30(5):228–235
Suzuki K, Harada A, Shiraishi E, Kimura H (2015) In vivo pharmaco-
logical characterization of TAK-063, a potent and selective phos-
phodiesterase 10A inhibitor with antipsychotic-like activity in ro-
dents. J Pharmacol Exp Ther 352(3):471–479
Tarrier N (1987) An investigation of residual psychotic symptoms in
discharged schizophrenic patients. Br J Clin Psychol 26(Pt 2):141–143
Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR (2009)
Inhibition of phosphodiesterase 10A increases the responsiveness
of striatal projection neurons to cortical stimulation. J Pharmacol
Exp Ther 328(3):785–795
Psychopharmacology (2016) 233:3787–3795 3795
